PriceSpective appoints Bob Nordyke to lead new unit
This article was originally published in Scrip
PriceSpective, a consultancy providing pricing and reimbursement services to pharmaceutical, biotechnology and healthcare companies, has appointed Bob Nordyke to lead its new Health Economics and Outcomes Research (HEOR) practice. He has more than 18 years' HEOR experience, having previously worked as part of the global health economics team at Amgen where he served in various roles, including therapeutic area head for inflammation, global payer lead and global health economics lead for haematology/oncology and programme lead for EMR-based registry capability for oncology. Before Amgen, Mr Nordyke was director of outcomes research at Cerner LifeSciences and a research fellow at the RAND Corporation.